EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

I Ray-Coquard, A Leary, S Pignata, C Cropet, A González-Martín, C Marth, S Nagao, I Vergote, N Colombo, J Mäenpää, F Selle, J Sehouli und 19 weitere

Annals of Oncology · 2023-08 · 34 (8) · 681-692

DOI: 10.1016/j.annonc.2023.05.005 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of Oncology, 2023-08. Verfasst von I Ray-Coquard und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Centre Léon Bernard, Lyon, France; GINECO, France. Electronic address: isabelle.ray-coquard@lyon.unicancer.fr. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 389-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca plc, Roche, Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus bevacizumab demonstrated a significant progression-free survival (PFS) benefit in newly diagnosed advanced ovarian cancer patients in clinical response after first-line platinum-based chemotherapy plus bevacizumab, irrespective of surgical status. Prespecified, exploratory analyses by molecular biomarker status showed substantial benefit in patients with a BRCA1/BRCA2 mutation (BRCAm) or homologous recombination deficiency (HRD; BRCAm and/or genomic instability). We report the prespecified final overall survival (OS) analysis, including analyses by HRD status. PATIENTS AND METHODS: Patients were randomized 2 : 1 to olaparib (300 mg twice daily; up to 24 months) plus bevacizumab (15 mg/kg every 3 weeks; 15 months total) or placebo plus bevacizumab. Analysis of OS, a key secondary endpoint in hierarchical testing, was planned for ∼60% maturity or 3 years after the primary analysis. RESULTS: After median follow-up of 61.7 and 61.9 months in the olaparib and placebo arms, respectively, median OS was 56.5 versus 51.6 months in the intention-to-treat population [hazard ratio (HR) 0.92, 95% confidence interval (CI) 0.76-1.12; P = 0.4118]. Subsequent poly(ADP-ribose) polymerase inhibitor therapy was received by 105 (19.6%) olaparib patients versus 123 (45.7%) placebo patients. In the HRD-positive population, OS was longer with olaparib plus bevacizumab (HR 0.62, 95% CI 0.45-0.85; 5-year OS rate, 65.5% versus 48.4%); at 5 years, updated PFS also showed a higher proportion of olaparib plus bevacizumab patients without relapse (HR 0.41, 95% CI 0.32-0.54; 5-year PFS rate, 46.1% versus 19.2%). Myelodysplastic syndrome, acute myeloid leukemia, aplastic anemia, and new primary malignancy incidence remained low and balanced between arms. CONCLUSIONS: Olaparib plus bevacizumab provided clinically meaningful OS improvement for first-line patients with HRD-positive ovarian cancer. These prespecified exploratory analyses demonstrated improvement despite a high proportion of patients in the placebo arm receiving poly(ADP-ribose) polymerase inhibitors after progression, confirming the combination as one of the standards of care in this setting with the potential to enhance cure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsAntineoplastic AgentsHumansFemaleBevacizumabPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsMaintenance ChemotherapyPiperazines

Stichwörter der Autor:innen

advanced ovarian cancerbevacizumabolapariboverall survival

Substanzen

BevacizumabAntineoplastic AgentsPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsolaparibPiperazines

Autor:innen und Institutionen

  • Department of Medical Oncology, Centre Léon Bernard, Lyon, France; GINECO, France. Electronic address: isabelle.ray-coquard@lyon.unicancer.fr.
  • GINECO, France; Gynecological Cancer Unit, Department of Medicine, Institut Gustave Roussy, Villejuif France.
  • Department of Urology and Gynecology, Istituto Nazionale Tumori 'Fondazione G Pascale', IRCCS, Naples, Italy; MITO, Italy.
  • GINECO, France; Department of Biostatistics Centre Léon BERARD, Lyon, France.
  • Department of Medical Oncology, Clínica Universidad de Navarra, Program in Solid Tumors (CIMA), Pamplona, Spain; GEICO, Spain.
  • Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria; AGO Austria, Austria.

Förderung

  • AstraZeneca plc
  • Roche
  • Amgen
  • Merck Sharp & Dohme Ltd

Zitieren

APA

Ray-Coquard, I., Leary, A., Pignata, S., Cropet, C., González-Martín, A., Marth, C., Nagao, S., Vergote, I., Colombo, N., Mäenpää, J., Selle, F., Sehouli, J., Lorusso, D., Guerra Alia, E. M., Bogner, G., Yoshida, H., Lefeuvre-Plesse, C., Buderath, P., Mosconi, A. M., …, & PAOLA-1/ENGOT-ov25 investigators (2023). Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Annals of Oncology, 34(8), 681-692. https://doi.org/10.1016/j.annonc.2023.05.005

Vancouver

Ray-Coquard I, Leary A, Pignata S, Cropet C, González-Martín A, Marth C, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Annals of Oncology. 2023;34(8):681-692. doi:10.1016/j.annonc.2023.05.005

BibTeX
@article{RayCoquard2023,
  author = {Ray-Coquard, I and Leary, A and Pignata, S and Cropet, C and González-Martín, A and Marth, C and Nagao, S and Vergote, I and Colombo, N and Mäenpää, J and Selle, F and Sehouli, J and Lorusso, D and Guerra Alia, E M and Bogner, G and Yoshida, H and Lefeuvre-Plesse, C and Buderath, P and Mosconi, A M and Lortholary, A and Burges, A and Medioni, J and El-Balat, A and Rodrigues, M and Park-Simon, T-W and Dubot, C and Denschlag, D and You, B and Pujade-Lauraine, E and Harter, P and PAOLA-1/ENGOT-ov25 investigators, PAOLA-1/ENGOT-ov25 investigators},
  title = {Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial},
  journal = {Annals of Oncology},
  year = {2023},
  volume = {34},
  number = {8},
  pages = {681--692},
  doi = {10.1016/j.annonc.2023.05.005}
}
Kostenlos starten →